الصفحة الرئيسية>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Acetyltransferases>>GSK4028

GSK4028

رقم الكتالوجGC30714

GSK4028 هو عنصر تحكم سلبي متماثل لـ GSK4027 ، وهو عبارة عن مسبار كيميائي برومودومين PCAF / GCN5 ، و pIC50 لـ GSK4028 هو 4.9 في مقايسة نقل طاقة الرنين الفلوري الذي تم حله بمرور الوقت (TR-FRET)

Products are for research use only. Not for human use. We do not sell to patients.

GSK4028 التركيب الكيميائي

Cas No.: 2079886-19-2

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
129٫00
متوفر
5mg
117٫00
متوفر
10mg
198٫00
متوفر
25mg
405٫00
متوفر
50mg
684٫00
متوفر
100mg
1125٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.

GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9. GSK4028 also demonstrates potency toward BRD4 BD1 and BRD9 inTR-FRET assay with pIC50s of <4.3 and 4.5±0.13, respectively[1].

[1]. Humphreys PG, et al. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe. J Med Chem. 2017 Jan 26;60(2):695-709.

مراجعات

Review for GSK4028

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GSK4028

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.